Abstract
Corrigendum to ‘The evolution of clonality testing in the diagnosis and monitoring of hematological malignancies’ published in Therapeutic Advances in Hematology 2014; 5(2): 35–47. DOI: 10.1177/2040620713519729.
On page 42 of this article, the captions for Figures 3 and 4 should be read as shown below:
Figure 3. IGH high-throughput sequencing analysis of polyclonal (A) and monoclonal (B) cell populations. The analysis was performed by LymphoTrack IGH assay (Invivoscribe Technologies, Inc., San Diego, CA).
Figure 4. IGH high-throughput sequencing analysis of irregular polyclonal (A) and biallelic or biclonal (B) cell populations. The analysis was performed by LymphoTrack IGH assay (Invivoscribe Technologies, Inc., San Diego, CA).